Alcohol and the liver

Current Opinion in Gastroenterology

Volumn 23, Issue 3, 2007, Pages 283-291

  Reuben, Adrian ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE   (United States)

Author keywords

Alcoholic liver disease; Biomarkers; Endoplasmic reticulum stress; Liver transplantation; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CALCIUM CARBIMIDE; DISULFIRAM; GLUCURONIDE; NALOXONE; PREDNISONE;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOL REHABILITATION PROGRAM; ALCOHOLISM; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOPLASMIC RETICULUM; EPIDEMIOLOGICAL DATA; GENETIC MARKER; GENETIC PREDISPOSITION; HUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

ALCOHOL DRINKING; ANIMALS; ANTIOXIDANTS; HUMANS; LIPOTROPIC AGENTS; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MORBIDITY; PROGNOSIS; WORLD HEALTH;

EID: 34147172918     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3280f27582     Document Type: Review

References (152)

1. Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2006; 22:263-271.
2. National Survey on Drug Use and Health. Substance use and substance use disorders among American Indians and Alaska Natives. http://www.oas.samhsa.gov/ 2k6/AmIndians.pdf. [Accessed 28 January 2007]
3. Office of Applied Statistics. Results from the National Survey on Drug Use and Health: National findings. DHHS Publication No. 06-4194. NSDUH Series H-30. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006.
4. ISBRA 2006 Congress. Alcohol Clin Exp Res 2006; 30 (9 Suppl):1A-189A.
5. Snyder LB, Milici FF, Slater M, et al. Effects of alcohol advertising exposure on drinking among youth. Arch Pediatr Adolesc Med 2006; 160:18-24. • Each additional advertisement has seen increases in the number of drinks consumed by 1%.
6. Stokkeland K, Brandt L, Ekbom A, et al. Morbidity and mortality in liver diseases in Sweden 1969-2001 in relation to alcohol consumption. Scand J Gastroenterol 2006; 41:463-468.
7. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006; 367:52-56. •• A disturbing increase in cirrhosis mortality in Britain contrasts with simultaneous improvement in Sweden.
8. Room R. British livers and British alcohol policy. Lancet 2006; 367:10-11.
9. Andreasson S, Holder HD, Norström E, Rossow I. Estimates of harm associated with changes in Swedish alcohol policy: results from past and present estimates. Addiction 2006; 101:1092-1105.
10. Kerr-Corrêa F, Igami TZ, Hiroce V, Tucci AM. Patterns of alcohol use between genders: a cross cultural evaluation. J Affect Disord 2006; 3 November [Epub ahead of print].
11. Morasco BJ, Pietrzak RN, Blanco C, et al. Health problems and medical utilization associated with gambling disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2006; 26:976-984.
12. Shore JH, Beals J, Orton H, Buchwald D. Comorbidity of alcohol abuse and dependence with medical conditions in 2 American Indian reservation communities. Alcohol Clin Exp Res 2006; 30:649-655.
13. Mehta MM, Moriarity KJ, Proctor D, et al. Alcohol misuse in older people: heavy consumption and protean presentations. J Epidemiol Comm Health 2006; 60:1048-1052. • Important reminder that Rabelais was correct about the abundance of 'old drunkards'.
14. Day CP. Genes or environment to determine alcoholic liver disease and nonalcoholic fatty liver disease. Liver Int 2006; 26:1021-1028.
15. Stephens D, Dudley R. The drunken monkey hypothesis. National History 2005; 113:40-44.
16. Dudley R. Ethanol, fruit ripening, and the historical origins of human alcoholism in primate frugivory. Integr Comp Biol 2004; 44:315-323.
17. Levey DJ. The evolutionary ecology of ethanol production and alcoholism. Integr Comp Biol 2004; 44:284-289.
18. Morris S, Humphreys D, Reynolds D. Myth, marula and elephant: an assessment of voluntary ethanol intoxication of the African elephant (Loxodonta africana) following feeding on the fruit of the marula tree (Sclerocarya birrea). Physiol Biochem Zool 2006; 79:363-369.
19. Stickel F, Österreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol 2006; 41:209-224.
20. Gemma S, Vichi S, Testai E. Individual susceptibility and alcohol effects: biochemical and genetic aspects. Ann Ist Super Sanità 2006; 42:8-16.
21. Lavik B, Holmegaard C, Becker U. Drinking patterns and biochemical signs of alcoholic liver disease in Danish and Greenlandic patients with alcohol addiction. Int J Circumpolar Health 2006; 65:219-227.
22. Xuei X, Dick D, Flury-Wetherill L, et al. Association of the Kappa-opioid system with alcohol dependence. Mol Psychiatry 2006; 11:1016-1024.
23. Connor M, Kitchen I. Has the sun set on kappa3-opioid receptors? Br J Pharmacol 2006; 147:349-350.
24. Olianas MC, Concas D, Onali P. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br J Pharmacol 2006; 147:360-370.
25. Duranceaux NC, Shuckit MA, Eng MY, et al. Association of variations in alcohol dehydrogenase genes with the level of response to alcohol in non-Asians. Alcohol Clin Exp Res 2006; 30:1470-1478.
26. Montane-Jaime K, Moore S, Shafe S, et al. ADH1C*2 allele is associated with alcohol dependence and elevated liver enzymes in Trinidad and Tobago. Alcohol 2006; 39:81-86.
27. Lorenzo A, Auguet T, Vidal F, et al. Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women. Drug and Alcohol Dependence 2006; 84:195-200.
28. Loza AJM, Iglesias MTR, Diaz IP, et al. Association of alcohol-metabolizing genes with alcoholism in a Mexican Indian (Otomi) population. Alcohol 2006; 39:73-79.
29. Komiya Y, Nakao H, Kuroda Y, et al. Application of aldehyde dehydrogenase 2 (ALDH2) genetic diagnosis in support of decreasing alcohol intake. J Occup Health 2006; 48:161-165.
30. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006; 43:352-361. •• Skilful use of an extensive metaanalysis to show the inadequacies of published genetic polymorphism studies of AUD and ALD.
31. Puukka K, Hietala J, Koivisto H, et al. Additive effects of moderate drinking and obesity on serum g-glutamyl transferase activity. Am J Clin Nutr 2006; 83:1351-1354. • Reminder of the confounding effect of nonalcoholic liver disease on GGT levels.
32. Koivisto H, Hietala J, Anttila P, et al. Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications. J Lab Clin Med 2006; 14:191-196.
33. Hietala J, Koivisto H, Latvala J, et al. IgAs against acetaldehyde-modified red cell protein as a marker of ethanol consumption in male alcoholic subjects, moderate drinkers, and abstainers. Alc Clin Exp Res 2006; 30:1693-1698. • Interesting new possible biomarker for alcoholism.
34. Gariage M, Azuine MA, Lakshman MR. Chronic ethanol consumption upregulates the cytosolic and plasma membrane sialidase genes, but down-regulates lysosomal membrane sialidase gene in rat liver. Metabolism Clin Exp 2006; 55:803-810.
35. Gariage M, Gong M, Lakshman MR. Ethanol destabilizes liver Galβ1, 4 GlcNAc α2,6-sialyltransferase mRNA by depleting a 3′-untranslated region-specific binding protein. J Pharmacol Exp Ther 2006; 318:1076-1082.
36. Bortolotti F, De Paoli G, Tagliaro F. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005. J Chromatog B 2006; 841:96-109. • Useful review of the CDT story.
37. Arndt T, Gressner A, Herwig J, et al. Arginosuccinate lyase deficiency (ASL) and carbohydrate-deficient transferrin (CDT): experience with four independent CDT analysis methods - misleading results given by %CDT TIA assay. Clin Chim Acta 2006; 373:117-120.
38. Schöniger-Hekele M, Ramskogler K, Hartl D, Lesch OM. Exclusion of trisialotransferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease? Wien Med Woschenschr 2006; 156:216-222.
39. Arndt T, Meier U, Nauck M, Gressner AM. Primary biliary cirrhosis is not a clinical condition for increased carbohydrate-deficient transferrin: experience with four independent CDT analysis methods. Clin Chim Acta 2006; 372:184-187.
40. Arndt T. Valid carbohydrate-deficient transferrin testing. Clin Chim Acta 2006; 364:367-368.
41. Hietala J, Koivisto H, Anttila P, Niemelä O. Comparison of the combined marker GGT-CDT and the controversial laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2006; 41:528-533.
42. Taracha E, Habrat B, Chrapusta JJ, et al. Combining markers of nephrotoxicity and hepatotoxicity and detection of chronic alcohol abuse. Clin Chem Lab Med 2006; 44:1446-1452.
43. Schloegl H, Dresen S, Spaczynski K, et al. Stability of ethyl glucuronide in urine, postmortem tissue and blood samples. Int J Leg Med 2006; 120:83-88. • Reminder of the utility of ethyl glucuronide for the detection of alcohol abuse.
44. Nicholas PC, Kim D, Crews FT, MacDonald JM. Proton magnetic resonance spectroscopic determination of ethanol-induced formation of ethyl glucuronide in liver. Anal Biochem 2006; 358:185-191.
45. Schloegl H, Rost T, Schmidt W, et al. Distribution of ethyl glucuronide in rib marrow, other tissues and body liquids as proof of alcohol consumption before death. Forensic Sci Int 2006; 156:213-218.
46. Zimmer H, Schmitt G, Aderjan R. Preliminary immunochemical test for the determination of ethyl glucuronide in serum and urine: comparison of screening method results with gas chromatography-mass spectrometry. J Anal Toxicol 2002; 26:11-16.
47. Helander A, Dahl H. Urinary tract infection: a risk factor for false-negative urinary ethyl glucuronide but not ethyl sulfate in the detection of recent alcohol consumption. Clin Chem 2005; 51:1728-1730.
48. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101:76-82.
49. Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6:33.
50. Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006; 131:1057-1063. •• A possible solution for an increasingly common dilemma.
51. Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferases to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006; 101:1500-1508.
52. Thabut D, Naveau S, Charlotte F, et al. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatology 2006; 44:1175-1185. • Another attempt to circumvent liver biopsy by the group from Paris.
53. 1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcohol and nonalcoholic patients with cirrhosis with hepatic encephalopathy. Am J Neuroradiol 2006; 27:1019-1026.
54. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006; 65:278-290.
55. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology 2006; 43:S63-S74.
56. Ji C, Kaplowitz N. ER stress: can the liver cope? J Hepatol 2006; 45:321-333. •• A lucid account of oxidative stress in the endoplasmic reticulum and its relation to a wide spectrum of liver diseases.
57. Nishitani Y, Matsumoto H. Ethanol rapidly causes activation of JNK associated with ER stress under inhibition of ADH. FEBS Lett 2006; 580:9-14.
58. Cederbaum AI. CYP2E1: biochemical and toxicological aspects and role in alcohol-induced liver injury. Mount Sinai J Med 2006; 73:567-672. • Good overview of the role of CYP2E1 induction by alcohol and its role in ALD.
59. Bardag-Gorce F, French BA, Nan L, et al. CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol 2006; 81:191-201. •• First report of Mallory body-like formation in transformed human liver cells in vitro.
60. Zhuge J, Cederbaum AI. Increased toxicity by transforming growth factor-beta 1 in liver cells overexpressing CYP2E1. Free Radic Biol Med 2006; 41:1100-1112.
61. He P, Count MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation in human liver microsomes. Drug Metab Dispos 2006; 34:1198-1207.
62. Yuan G-J, Zhou X-R,Gong Z-J, et al. Expression and activity of inducible nitric oxide synthase and endothelial nitric oxide synthase correlate with ethanol-induced liver injury. World J Gastroenterol 2006; 12:2375-2381.
63. Gyamfi MA, Wan Y-JY. The effect of ethanol, ethanol metabolizing enzyme inhibitors, and vitamin E on regulating glutathione, glutathione-S-transferase, and S-adenosyl methionine in mouse primary hepatocytes. Hepatol Res 2006; 35:53-61.
64. Mallikarjuna K, Nishanth K, Reddy KS. Hepatic glutathione mediated antioxidant system in ethanol treated rats: decline with age. Pathophysiology 2006; 24 October [Epub ahead of print].
65. Jean S, Kasinathan C, Buyske S, Manowitz P. Ethanol decreases rat hepatic arylsulfatase A activity levels. Alcohol Clin Exp Res 2006; 30:1950-1955.
66. Wu H, Cai P, Clemens DL, et al. Metabolic basis of ethanol-induced cytotoxicity in recombinant HepG2 cells: role of nonoxidative metabolism. Toxicol Appl Pharmacol 2006; 216:238-247.
67. Bhopale KK, Wu H, Boor PJ, et al. Metabolic basis of ethanol-induced hepatic and pancreatic injury in hepatic alcohol dehydrogenase deficient deer mice. Alcohol 2006; 39:179-188.
68. López-Valencia V, Rangel P, Rodríguez S, Hernández-Munõz R. Involvement of alcohol and aldehyde dehydrogenase activities on hepatic retinoid metabolism and its possible participation in the progression of rat liver regeneration. Biochem Pharmacol 2007; 73:586-596.
69. Gyamfi MA, Kocsis MG, He L, et al. The role of retinoid X receptor in regulating alcohol metabolism. J Pharmacol Exp Ther 2006; 319:360-368. • A new facet to the regulation of alcohol metabolism: the nuclear receptor family.
70. Kannarkat GT, Tuma DT, Tuma PL. Microtubules are more stable and more highlyacetylated in ethanol-treated hepatic cells. J Hepatol 2006;44:963-970.
71. Moon K-H, Hood BL, Kim B-J, et al. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology 2006; 44:1218-1230.
72. McVicker BL, Tuma DJ, Kubik JL, et al. Ethanol-induced apoptosis in polarized hepatic cells possibly through regulation of the Fas pathway. Alcohol Clin Exp Res 2006; 30:1906-1915.
73. Crews FT, Bechara R, Brown LA, et al. Cytokines and alcohol. Alc Clin Exp Res 2006; 30:720-730.
74. Gobejishvili L, Barve S, Joshi-Barve S, et al. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NFκB activity and TNF expression: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2006; 291:G681-G688.
75. Drechster Y, Dolganuic A, Norkina O, et al. Heme oxygenase-1 mediates the anti-inflammatory effects of acute alcohol on IL-10 induction involving p38 MAPK activation in monocytes. J Immunol 2006; 177:2592-2600.
76. Naveau S, Perlemutter G, Chaillich M, et al. Serum leptin in patients with alcoholic liver disease. Alcohol Clin Exp Res 2006; 30:1422-1428.
77. Balasubramaniyan V, Viswanathan P, Nalini N. Effects of leptin administration on membrane-bound adenosine triphosphatase activity in ethanol-induced experimental liver toxicity. J Pharm Pharmcol 2006; 58:1113-1119.
78. Chen X, Sebastian BM, Nagy LE. Chronic ethanol feeding to rats decreases adiponectin secretion by subcutaneous adipocytes. Am J Physiol Endocrinol Metab 2007; 292:E621-E628.
79. Roberts RA, Ganey PE, Ju C, et al. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2006; 22 November [Epub ahead of print].
80. Cubero FJ, Nieto N. Kupffer cells and alcoholic liver disease. Rev Esp Enferm Dig 2006; 98:460-472.
81. Wang J-H, Batey RG, George J. Role of ethanol in the regulation of hepatic stellate cell function. World J Gastroenterol 2006; 12:6926-6932.
82. Brown LAS, Cook RT, Jerrells TR, et al. Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res 2006; 30:1624-1631.
83. Gustot T, Lemmers A, Moreno C, et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 2006; 43:989-1000.
84. Ferrier L, Bérard F, Debrauwer L, et al. Impairment of the intestinal barrier by ethanol involves mesenteric microflora and mast cell activation in rodents. Am J Pathol 2006; 168:1148-1154.
85. Pruett BS, Pruett SB. An explanation for the paradoxical induction and suppression of an acute phase response by ethanol. Alcohol 2006; 39:105-110.
86. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3:47-52.
87. Tsui JI, Pletcher MJ, Vittinghoff E, et al. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006; 44:262-266.
88. Manolakopoulos S, Economou M, Bethanis S, et al. A single alcohol ingestion does not affect serum hepatitis C virus RNA in patients with chronic hepatitis C. Liver Int 2006; 26:1196-1200.
89. Szabo G, Aloman C, Polyak SJ, et al. Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 2006; 30:709-719. • A Symposium report.
90. Lederer SL, Walters K-A, Proll S, et al. Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. Virol J 2006; 3:98.
91. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130:1607-1616. • Results of a large study showing how alcohol interferes with hepatitis C therapy.
92. Palepu A, Cheng DM, Kim T, et al. Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problems. J Subst Abuse Treat 2006; 31:411-417.
93. Nunes D, Saitz R, Libman H, et al. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006; 30:1520-1526.
94. Everhart JE. Alcohol and hepatitis C: do we have a drinking problem? Gastroenterology 2006; 130:1912-1919.
95. Homann N, Stickel F, König IR, et al. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 2006; 118:1998-2002.
96. Ogawa M, Oyama T, Isse T, et al. A comparison of covalent binding of ethanol metabolites to DNA according to Aldh2 genotype. Toxicol Lett 2007; 168:148-154.
97. Sakamoto T, Hara M, Higaki Y, et al. Influence of alcohol consumption and gene polymorphisms of ADH2 and ALDH2 on hepatocellular carcinoma in a Japanese population. Int J Cancer 2006; 118:1501-1507.
98. Shukla SD, Aroor AR. Epigenetic effects of ethanol on liver and gastrointestinal injury. World J Gastroenterol 2006; 12:5265-5271.
99. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of epidemiologic evidence. Oncogene 2006; 25:3756-3770.
100. Franceschi S, Montella M, Polesel J, et al. Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy. Cancer Epidemiol Biomarkers Prev 2006; 15:683-689.
101. Lodato F, Mazzella G, Festi D, et al. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constrains of developing nations. World J Gastroenterol 2006; 12:7239-7249.
102. Fukushima W, Tanaka T, Ohfuji S, et al. Does alcohol increase the risk of hepatocellular carcinoma among patients with hepatitis C virus infection? Hepatol Res 2006; 34:141-149. • In this study, the answer is no.
103. Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity and insulin resistance on survival in male cancer patients: National Health Insurance Corporation study. J Clin Oncol 2006; 24:5017-5024.
104. Boffetta P, Hashibe M, La Vecchia C, et al. The burden of cancer attributable to alcohol drinking. Int J Cancer 2006; 119:884-887.
105. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7:149-156.
106. McGinnis KA, Fultz SL, Skanderson M, et al. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24:5005-5009.
107. Sola R, Álvarez MA, Ballesté B, et al. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis: a study of 377 patients. Liver Int 2006; 26:62-72.
108. Gleeson D, Evans S, Bradley M, et al. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and normal controls. Am J Gastroenterol 2006; 101:304-310. • There is no influence of HFE on ALD.
109. Bridle KR, Cheung T-K, Murphy TL, et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006; 30:106-112.
110. Harrison-Findik DD, Schafer D, Klein E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 2006; 281:22974-22982. • Possible explanation for ALD-associated iron overload.
111. Beulens JWJ, van Beers RM, Stolk RP, et al. The effect of moderate alcohol consumption on fat distribution and adipocytokines. Obesity 2006; 14:60-66.
112. He L, Simmen FA, Mehendale HM, et al. Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane: role of TRB3 in inhibition of AKt/protein kinase B activation. J Biol Chem 2006; 281:11126-11134.
113. Suzuki Y, Ando F,Ohsawa I, et al. Association of alcohol dehydrogenase 2*1 allele with liver damage and insulin concentration in the Japanese. J Hum Genet 2006; 51:31-37.
114. Koçkaya EA, Akay MT. Histological changes in the liver of fetuses of alcohol-treated pregnant rats. Cell Biochem Funct 2006; 24:223-227.
115. Perez MJ, Velasco E, Monte MJ, et al. Maternal ethanol consumption during pregnancy enhances bile acid-induced oxidative stress and apoptosis in fetal rat liver. Toxicology 2006; 225:183-194.
116. Wentzel P, Eriksson UJ. Ethanol-induced fetal dysmorphogenesis in the mouse is diminished by high antioxidative capacity of the mother. Toxicol Sci 2006; 92:416-422.
117. Wentzel P, Rydberg U, Eriksson UJ. Antioxidative treatment diminishes ethanol-induced congenital malformations in the rat. Alcohol Clin Exp Res 2006; 30:1752-1760.
118. Jacobson SW, Carr LG, Croxford J, et al. Protective effects of the alcohol dehydrogenase-ADH1B allele in children exposed to alcohol during pregnancy. J Pediatr 2006; 148:30-37.
119. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4:24-34. •• Very good current guidelines.
120. Berry PA, Wendon JA. The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. Curr Opin Crit Care 2006; 12:171-177.
121. Ceccanti M, Attili A, Balducci G, et al. Acute alcoholic hepatitis. J Clin Gastroenterol 2006; 40:833-841.
122. Rongey C, Kaplowitz N. Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol 2006; 12:6909-6921. •The problem is well stated in this comprehensive and concise review.
123. Phillips M, Curtis H, Portmann B, et al. Antioxidants versus corticosteroids in the treatment of severe alcohol hepatitis: a randomized clinical trial. J Hepatol 2006; 44:784-790. • Steroids win.
124. O'Shea R, McCullough AJ. Steroids or cocktails for alcoholic hepatitis. J Hepatol 2006; 44:633-636.
125. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver disease. Cochrane Database Syst Rev 2006; (2):CD002235. • S-adenosyl-L- methionine loses.
126. Rambaldi A, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2006; (4):CD003045. • Androgens lose.
127. Bolkent S, Arda-Pirincci P, Bolkent S, et al. Influence of zinc sulfate intake on acute ethanol-induced liver injury in rats. World J Gastroenterol 2006; 12:4345-4351.
128. Song Z, Deaciuc I, Song M, et al. Silymarin protects against acute ethanol-induced hepatotoxicity in mice. Alcohol Clin Exp Res 2006; 30:407-413.
129. Izu H, Shobayashi M, Manabe Y, et al. S-adenosylmethionine (SAM)-accumulating Sake yeast suppresses acute alcohol-induced liver injury in mice. Biosci Biotechnol Biochem 2006; 70:2982-2989.
130. Izu H, Shobayashi M, Manabe Y, et al. Sake yeast suppresses acute alcohol induced liver injury in mice. Biosci Biotechnol Biochem 2006; 70:2488-2493.
131. Singha PK, Roy S, Dey S. Protective activity of andrographolide and arabinogalactan proteins from Andrographis paniculata Nees. against ethanol-induced toxicity in mice. J Ethnopharmacol 2006; 28 October [Epub ahead of print].
132. Bergheim I, Guo L, Davis MA, et al. Metformin prevents alcohol-induced liver injury in the mouse: critical role of plasminogen activator inhibitor-1. Gastroenterology 2006; 130:2099-2112.
133. Saravanan R, Viswanathan P, Pugalendi KV. Protective effect of ursolic acid on ethanol-mediated experimental liver damage in rats. Life Sci 2006; 78:713-718.
134. Cowpland C, Su GM, Murray M, et al. Effect of alcohol on cytochrome P450 arachidonic acid metabolism and blood pressure in rats and its modulation by red wine polyphenolics. Clin Exp Pharmacol Physiol 2006; 33:183-188.
135. Zang X-G, Xu P, Liu Q, et al. Effect of tea polyphenol on cytokine gene expression in rats with alcoholic liver disease. Hepatobiliary Pancreat Dis Int 2006; 5:268-272.
136. Bujanda L, García-Barcina M, Gutiérrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006; 6:35.
137. Wang A-L, Wang J-P, Wang H, et al. A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice. Hepatol Res 2006; 34:199-206.
138. Kaviarsasan S, Ramamurty N, Gunasekaran P, et al. Fenugreek (Trigonella foenum graecum) seed extract prevents ethanol-induced toxicity and apoptosis in Chang liver cells. Alcohol Alcohol 2006; 41:267-273.
139. Shimada M, Liu L, Nussler N, et al. Human hepatocytes are protected from ethanol-induced cytotoxicity by DADS via CYP2E1 inhibition. Toxicol Lett 2006; 163:242-249.
140. Norikura T, Kojima-Yuasa A, Opare Kennedy D, Matsui-Yasa I. Protective effect of gamma-aminobutyric acid (GABA) against cytotoxicity of ethanol in isolated rate hepatocytes involves modulations in cellular polyamine levels. Amino Acids 2006; 29 August [Epub ahead of print].
141. Nieto N, Rojkind M. Repeated whiskey binges promote liver injury in rats fed a choline-deficient diet. J Hepatol 2007; 46:330-339.
142. Samara K, Liu C, Soldevila-Pico C, et al. Betaine resolves severe alcoholinduced hepatitis and steatosis following liver transplantation. Dig Dis Sci 2006; 51:1226-1229.
143. Verrill C, Smith S, Sheron N. Are the opportunities to prevent alcohol related liver deaths in the UK in primary or secondary care? A retrospective clinical review and prospective interview study. Substance Abuse Treat Prev Policy 2006; 1:16.
144. Verge C, Lucena MI, López-Torres E, et al. Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: is there still a role for these drugs? World J Gastroenterol 2006; 12:5078-5080.
145. Smith S, White J, Nelson C, et al. Severe alcohol-induced liver disease and the alcohol-dependence syndrome. Alcohol Alcohol 2006; 41:274-277.
146. O'Grady JG. Liver transplantation alcohol related liver disease: (deliberately) stirring a hornet's nest! Gut 2006; 55:1529-1531.
147. Bathgate AJ and UK Transplant Units. Recommendations for alcohol-related liver disease. Lancet Oncol 2006; 367:2045-2046. • Sensible guidelines.
148. DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 2006; 12:813-820. •• Outstanding study of relapse of alcohol use in liver recipients and possible predictive factors.
149. McCallum S, Masterton G. Liver transplantation for alcoholic liver disease: a systematic review of psychosocial selection criteria. Alcohol Alcohol 2006; 41:358-363.
150. Kelly M, Chick J, Gribble R, et al. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol 2006; 41:278-283.
151. Bramstedt KA, Jabbour N. When alcohol abstinence criteria create ethical dilemmas for the liver transplant team. J Med Ethics 2006; 32:263-265.
152. Hwang S, Lee SG, Kim KK, et al. Efficacy of 6-month pretransplant abstinence for patients with alcoholic liver disease undergoing living donor liver transplantation. Transplant Proc 2006; 38:2937-2940. • Recipients of living-donor liver grafts must be abstinent too.